Skip to content

Lawyers
Jenene Roberts listen

About

Jenene* has spent her 15-year career specializing in intellectual property litigation, with significant success representing pharmaceutical clients in complex patent litigation. With a strong combination of technical knowledge and legal skills, Jenene pays§ dividends for clients. She is a strategic thinker who knows how to move matters forward in her clients’ best interests. Also known for her meticulous nature, Jenene shows close attention to detail in her cases, ensuring that nothing is missed when analyzing difficult legal questions and identifying the right solutions. .

Expertise

  • Practice Areas:
  • Bar Admissions:
    • Ontario (2006)
  • Education:
    • Osgoode Hall Law School (2005) LLB
    • Memorial University of Newfoundland (2002) BSc (Chemistry) (Honours)

Details

Jenene Roberts (she/her)

is counsel at Lenczner Slaght.

Jenene practises in the area of intellectual property litigation. With a particular focus on patent litigation, Jenene has significant experience and expertise in litigating cases in the pharmaceutical industry. She also appears regularly before the Federal Court of Canada in complex patent litigation, and has appeared before the Federal Court of Appeal.

Jenene is also a registered trademark agent. She has been involved in trademark opposition proceedings and expungement proceedings, having appeared before the Trademarks Opposition Board.

Prior to law school, Jenene worked as a research assistant for three years as an undergraduate chemistry student at Memorial University of Newfoundland, where she was also a recipient of numerous awards, including The Captain Robert A. Bartlett Science Award as the top undergraduate student graduating from the Faculty of Science.

  • Bristol-Myers Squibb Canada v Apotex Inc

    Counsel to a generic pharmaceutical company in the successful motion for summary dismissal of patent proceedings relating to the drug aripiprazole, which is used to treat schizophrenia, on the basis of non-infringement. (Prior to joining Lenczner Slaght.)

    Jenene Roberts | January 1, 2021

  • Valeant Canada LP v Apotex Inc

    Counsel to a generic pharmaceutical company in the successful motion for summary dismissal of patent proceedings relating to the drug metformin, which is used to treat diabetes, on the basis of non-infringement. (Prior to joining Lenczner Slaght.)

    Jenene Roberts | January 1, 2021

  • Eli Lilly Canada Inc v Apotex Inc

    Counsel to a generic pharmaceutical company in the successful dismissal of a patent proceeding relating to the drug prasugrel, which is used to prevent blood clots, on the basis of obviousness. (Prior to joining Lenczner Slaght.)

    Jenene Roberts | January 1, 2021

  • Janssen Inc v Apotex Inc

    Counsel to a generic pharmaceutical company in the successful dismissal of a patent proceeding relating to the drug abiraterone, which is used to treat prostate cancer, on the basis of obviousness. (Prior to joining Lenczner Slaght.)

    Jenene Roberts | January 1, 2021

  • Takeda Canada Inc v Canada (Health)

    Counsel to a generic pharmaceutical company in the successful dismissal of a patent proceeding involving three patents relating to the nasal spray ciclesonide, on the basis of obviousness. (Prior to joining Lenczner Slaght.)

    Jenene Roberts | January 1, 2015

  • Bayer Inc v Apotex Inc

    Counsel to a generic pharmaceutical company in the successful dismissal of a patent proceeding relating to the birth control drug drospirenone, on the basis of non-infringement. (Prior to joining Lenczner Slaght.)

    Jenene Roberts | January 1, 2014

  • Teva Canada Innovation v Apotex Inc

    Counsel to a generic pharmaceutical company in the successful dismissal of a patent proceeding relating to the drug rasagiline, which is used for the treatment of Parkinson’s disease, on the basis of non-infringement. (Prior to joining Lenczner Slaght.)

    Jenene Roberts | January 1, 2014

  • Hoffman-La Roche Limited v Apotex Inc

    Counsel to a generic pharmaceutical company in the successful dismissal of a patent proceeding relating to the drug rasagiline, which is used for the treatment of Parkinson’s disease, on the basis of non-infringement. (Prior to joining Lenczner Slaght.)

    Jenene Roberts | January 1, 2013

  • The Advocates' Society

scroll
Back to top